Related coverage linked through entity extraction aliases.
Aug 20, 2026
Longeveron appoints Nirav Jhaveri as CFO, succeeding Marie Washburn. The company anticipates Phase 2b trial results for laromestrocel in HLHS in September, with FDA guidance that a successful trial would be pivotal for BLA filing.
Aug 19, 2026
Silo Pharma received a European patent grant and a Japan patent allowance for SPC-15, its intranasal PTSD prevention candidate. The patents cover methods using serotonin 4 receptor agonists to prevent stress-induced psychiatric disorders.
Aug 17, 2026
Alpha-synuclein biomarkers in saliva, skin, and CSF show diagnostic promise for Parkinson's disease, with seed amplification assays demonstrating high sensitivity and specificity. Salivary gland biopsies and oral brushings are being studied as less invasive detection methods, though clinical implementation still faces challenges.
Apr 22, 2026
Roche's Elecsys pTau181 test received FDA clearance for primary care use, and its Elecsys ApoE4 test earned CE Mark approval. Despite these advances, Medicare does not cover Alzheimer's blood biomarker screenings before symptoms appear, prompting the bipartisan ASAP Act.
Jul 03, 2026
Biogen's Phase 2 CELIA trial showed diranersen slowed Alzheimer's decline and cut tau biomarkers, but missed the dose-response goal. Leqembi sales data is expected next quarter.
Aug 03, 2026
FDA approved a subcutaneous starting dose of Leqembi for early Alzheimer's disease. AAIC 2026 real-world data showed most patients stable or improved; a mouse study found KCL-286 repaired DNA damage and reduced inflammation.
Jul 31, 2026
Prothena Corporation plc will report its second quarter and first six months of 2026 financial results on August 6, 2026, after U.S. market close. No conference call will be held, consistent with past practice. The company focuses on neurodegenerative and rare amyloid diseases.
May 07, 2026
Alzheimer's blood tests are gaining FDA clearances and strong patient interest, yet surveys show clinicians remain skeptical about their reliability and clinical benefit. A UK survey found fewer than one-third of psychiatrists have used biomarkers, while only 6% of memory services meet access guidelines. An ethical framework urges careful implementation, especially in primary care.
Jun 23, 2026
Cerebral organoids are revealing how Ebola virus persists, aiding treatment research for rare Parkinson's disease, modeling Alzheimer's, and gaining whole-network recording capabilities.
Aug 05, 2026
Oncotelic granted Lunai Bioworks worldwide rights to its nose-to-brain delivery system for biodefense and Alzheimer's. Nearly 98% of small-molecule drugs fail to cross the blood-brain barrier.
Aug 01, 2026
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
Jul 01, 2026
New reports project clinical trials markets to grow sharply: decentralized trials to $38.3B by 2035, omics-based trials to $47.78B by 2030, women's trials to $22.3B by 2036, and software to $34.15B by 2035.
Jun 16, 2026
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
Jul 24, 2026
An ultrasensitive test detects TDP-43 seeds in CSF to diagnose FTLD-TDP. At-home blood tests show promise for remote dementia triage, but primary care use of plasma biomarkers remains limited.
May 15, 2026
Phase 2 MINDFuL results for XPro1595 in early Alzheimer's disease were published, showing positive trends and no ARIA. FDA aligned on a phase 2b/3 registrational design. Webinar set for Feb 27, 2026.
Aug 04, 2026
New 3D brain tissue models, laser imaging, and organoid sensors aim to speed drug development for Alzheimer’s and other neurological diseases. The LMU model replicates Alzheimer’s aggregates, MIT’s laser images the blood-brain barrier at record speed, and UNC’s sensor records neural activity without damaging organoids.
Aug 02, 2026
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
Jul 23, 2026
Tortugas Neuroscience and Korsana Biosciences emerged with significant funding to advance clinical-stage pipelines targeting neurological and neurodegenerative diseases. Tortugas raised $106 million, while Korsana secured $175 million to develop therapies for conditions including Alzheimer's, schizophrenia, and epilepsy.
Jul 17, 2026
A clinical study explores whether echocardiography can detect heart amyloid as an early sign of Alzheimer’s, while laboratory research maps a biphasic gene expression cascade in the brain that identifies new therapeutic targets.
Jul 15, 2026
A preclinical study shows that the anti-epileptic drug levetiracetam can prevent the formation of amyloid-beta 42 in neurons by modulating synaptic vesicle recycling. Analysis of patient records indicates a modest delay in cognitive decline among Alzheimer's patients taking the drug, suggesting potential for very early preventive use.
